In a pooled analysis of four prospective neoadjuvant clinical trials (GeparSepto, GeparOcto, GeparX, Gain-2 neoadjuvant), HER2-low breast cancer presented a significantly lower pCR rate than HER2-zero patients did (17). This evidence concerns the gene ERBB2 and breast cancer.